Evidence map›Paper›PMID 10318942›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America1999

Defining therapeutic targets by using adenovirus: blocking NF-kappaB inhibits both inflammatory and destructive mechanisms in rheumatoid synovium but spares anti-inflammatory mediators.

J Bondeson, B Foxwell, F Brennan, M Feldmann

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
9.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 209 citations in OpenAlex.

  1. Trial
  2. Article
  3. Proteasome Inhibitors: Potential in Rheumatoid Arthritis Therapy?International journal of molecular sciences · 2025
    Review
  4. Review
  5. Article
  6. Article
  7. Cytokine Networks in the Pathogenesis of Rheumatoid Arthritis.International journal of molecular sciences · 2021
    Review
  8. Article
  9. Article
  10. Frontiers in pharmacology · 2021
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Celastrol and Its Role in Controlling Chronic Diseases.Advances in experimental medicine and biology · 2016
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

J BondesonKennedy Institute of Rheumatology, 1 Aspenlea Road, Hammersmith, London W6 8LH, United Kingdom.
B Foxwell
F Brennan
M Feldmann

Funding

Wellcome Trust
6 · The paper itself

Abstract

The role of the transcription factor NF-kappaB in the pathogenesis of rheumatoid arthritis has long been a subject of controversy. We used an adenoviral technique of blocking NF-kappaB through overexpression of the inhibitory subunit IkappaBalpha, which has the advantage that it can be used in the diseased tissue itself, with >90% of the synovial macrophages, fibroblasts, and T cells infected. We found that the spontaneous production of tumor necrosis factor alpha and other pro-inflammatory cytokines is NF-kappaB-dependent in rheumatoid synovial tissue, in contrast to the main anti-inflammatory mediators, like IL-10 and -11, and the IL-1 receptor antagonist. Of even more interest, IkappaBalpha overexpression inhibited the production of matrix metalloproteinases 1 and 3 while not affecting their tissue inhibitor. Blocking NF-kappaB in the rheumatoid joint thus has a very beneficial profile, reducing both the inflammatory response and the tissue destruction. The adenoviral technique described here has widespread applicability, allowing rapid testing of the effects of blocking a potential therapeutic target in either cultures of normal cells or in the diseased tissue itself.

Indexed as

I-kappa B ProteinsAdenoviridaeAnti-Inflammatory AgentsArthritis, RheumatoidCells, CulturedCytokinesDNA-Binding ProteinsHumansInflammationLymphocytesMacrophagesMetalloendopeptidasesNF-kappa BNF-KappaB Inhibitor alphaSynovial MembraneTime FactorsAnti-Inflammatory AgentsCytokinesDNA-Binding ProteinsI-kappa B ProteinsMetalloendopeptidasesNF-kappa BNF-KappaB Inhibitor alphaNFKBIA protein, humanTissue Inhibitor of Metalloproteinases

Identifiers

PMID10318942
PMCPMC21918
OpenAlexW2159891151

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.